Molecular Functions of Hydrogen Sulfide in Cancer

Rodney E. Shackelford 1,*, Islam Z. Mohammad 1, Andrew T. Meram 2, David Kim 2, Fawaz Alotaibi 2, Stavan Patel 2, Ghali E. Ghali 2 and Christopher G. Kevil 1

1 Department of Pathology & Translational Pathobiology, LSU Health Sciences Center Shreveport, Shreveport, LA 71130, USA; mohammad.islam@lsuhs.edu (I.Z.M.); chris.kevil@lsuhs.edu (C.G.K.)
2 Head & Neck Oncologic/Microvascular Reconstructive Surgery Department of Oral & Maxillofacial/Head & Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA; andrew.meram@lsuhs.edu (A.T.M.); david.kim@lsuhs.edu (D.K.); falota@lsuhsc.edu (F.A.);
stavan.patel@lsuhs.edu (S.P.); gghali@lsuhs.edu (G.E.G.)
* Correspondence: Rodney.Shackelford@lsuhs.edu; Tel.: +1-318-525-6479

Abstract: Hydrogen sulfide (H2S) is a gasotransmitter that exerts a multitude of functions in both physiologic and pathophysiologic processes. H2S-synthesizing enzymes are increased in a variety of human malignancies, including colon, prostate, breast, renal, uterine, ovarian, oral squamous cell, and thyroid cancers. In cancer, H2S promotes tumor growth, cellular and mitochondrial bioenergetics, migration, invasion, angiogenesis, tumor blood flow, metastasis, epithelia–mesenchymal transition, DNA repair, protein sulfhydration, and chemotherapy resistance. Additionally, in some malignancies, increased H2S-synthesizing enzyme expression correlates with a worse prognosis and a higher tumor stage. Here we review the role of H2S in cancer, with an emphasis on the molecular mechanisms by which H2S promotes cancer development, progression, dedifferentiation, and metastasis.

Keywords: hydrogen sulfide; H2S; cancer; cystathionine β-synthase; cystathionine γ-lyase; 3-mercaptopuruvate sulfurtransferase

1. Introduction

Hydrogen sulfide (H2S) is a colorless, corrosive gas with a characteristic rotten egg smell, known for over 300 years as an environmental toxin [1]. High H2S concentrations cause damage in many organs, including the brain, kidneys, and lungs. Its toxic mechanisms are usually attributed to cytochrome C oxidase, Na+/K+ ATPase, carbonic anhydrase, monoamine oxidase, and possibly ATR kinase inhibition [1–4]. While H2S has been identified in mammalian tissues for decades, it was not until 1996 that endogenous H2S synthesis and function as a biological modulator in humans was identified [5]. Presently, along with nitric oxide and carbon monoxide, H2S is recognized as the third gasotransmitter and functions as a master regulator of many different physiologic and pathologic processes [6,7]. For example, H2S functions in the cardiovascular, renal, central nervous, and digestive systems [5,8–10]. Dysregulated H2S function is also seen in many diseases, including metabolic and Down’s syndromes, cardiovascular disease, neurodegeneration, and cancer [11–16].

2. H2S Chemistry, Synthesis, and Molecular Mechanisms of Action
2.1. H2S Chemistry

The biochemistry of H2S is ancient and was likely essential in the development of life along with its antecedent, pre-biotic chemistry [17]. H2S is a weak diprotic acid, with first and second pKa values of 6.76 and 19 at 37 °C. At the physiologic pH H2S is ~70–80% HS−, ~20% H2S, with low concentrations of S2− [18]. H2S readily passes through biological membranes allowing for efficient paracrine signaling, while HS− has a high nucleophilicity, conferring chemical reactivity [19,20]. Biological membranes are not significant barriers to H2S diffusion, possibly due to the rapid equilibrium between HS− and H2S [19].
minus two oxidation state of the sulfur in H$_2$S is the lowest possible sulfur oxidation state, making H$_2$S an obligatory reductant [7]. H$_2$S-oxidant interactions have been examined in many studies, where H$_2$S is reported to have antioxidant effects [21–24]. Interestingly, H$_2$S and H$_2$O$_2$ react too slowly to exert significant biologic effects [25,26]. Moreover, cellular H$_2$S concentrations are low at 10–30 nM, compared to other thiol-based antioxidants, such as glutathione at 1–10 mM. Thus, under biologic conditions it is unlikely that free H$_2$S has a quantitatively significant antioxidant role [27,28]. Most likely, a significant portion of H$_2$S-mediated antioxidant activity is due to its induction of other cellular antioxidant defense systems, such as increasing cystine uptake, and cellular glutathione (GSH) and cysteine concentrations [7,21]. Additionally, free H$_2$S exists in a thermodynamic equilibrium with many other sulfur species, including persulfides, polysulfides, and numerous sulfide metabolites, many of which are antioxidants [7]. In most tissues the H$_2$S half-life is short, lasting only a few minutes [7,29].

2.2. $H_2S$ Synthesis

$H_2S$ is chiefly synthesized by three systems: (1) cellular enzymes, (2) nonenzymatic synthesis, and (3) production by the microbiome. Enzymatic $H_2S$ synthesis is based on the reverse transsulfuration pathway, where dietary methionine is converted into homocysteine. Cystathionine β-synthase (CBS) then catalyzes the condensation of homocysteine with cysteine, yielding cystathionine and H$_2$S [30]. Cystathionine γ-lyase (CSE) catalyzes the conversion of cystathionine into α-ketobutyrate, cysteine, and NH$_3$ [30]. CBS and CSE are both pyridoxal 5′-phosphate-dependent enzymes and can catalyze other substrates, depending on the specific substrate concentrations [7,31]. For example, CSE also catalyzes the conversion of L-cysteine to thiocysteine, pyruvate, and NH$_3$. Thiocysteine in turn can non-enzymatically break down into pyruvate and H$_2$S. H$_2$S is also enzymatically synthesized by cysteine aminotransferase which converts cysteine to mercaptopyruvate, which 3-mercaptopyruvate sulfurtransferase (3-MST) in turn converts into H$_2$S and pyruvate [7,31].

CBS, CSE, and 3-MST show distinct tissue and subcellular distributions and exert different contributions to specific cell/tissue H$_2$S pools. 3-MST is primarily mitochondrial and synthesizes roughly 90% of brain H$_2$S [6,32]. CBS exists within many tissues but is predominantly seen in the central nervous system and liver, while CSE is predominantly located in the vasculature [30,31]. Intracellular H$_2$S exists as free H$_2$S, acid-labile sulfide, and bound sulfane sulfur [29]. Free cellular H$_2$S represents less than 1% of the potentially available sulfide, indicating that the endogenous sulfide pool likely has significant buffering capacity [7].

CBS, CSE, and 3-MST also synthesize polysulfides. In the brain, 3-MST synthesizes H$_2$S$_3$, which is known to alter the activities of proteins, such as KEAP1, PTEN, and GAPDH [33,34]. CSE overexpressing human A549 carcinoma cells have high polysulfide levels, while CSE knockout cells show significantly lower levels, and recently CSE-generated polysulfides have been shown to play a role in ovarian cancer [35,36]. Additionally, enzymatic kinetic analyses have shown that polysulfides are likely products of CBS and CSE activities [34]. Last, the enzyme cysteinyl tRNA synthetase produces protein hydropersulfides, which are involved in the regulation of mitochondrial biogenesis and bioenergetics, and many other cellular functions [37].

Nonenzymatic H$_2$S synthesis also accounts for a portion of H$_2$S synthesis and occurs by an iron and vitamin B$_6$-mediated catalysis of thiol and thiol-containing compounds, such as cysteine [38]. Last, the mammalian microbiome regulates the bioavailability and metabolism of systemic H$_2$S. For example, compared to conventionally housed mice, germ-free mice exhibit significantly lower plasma and gastrointestinal free H$_2$S, and 50–80% lower plasma, adipose, and lung tissue bound sulfane sulfur. Tissue CSE activity was also reduced in many of the organs in germ-free mice, while tissue cysteine levels were elevated [39].
2.3. Molecular Mechanisms of H$_2$S Activity

Based on its chemistry, the molecular mechanisms of H$_2$S reactivity have been placed into three categories: (1) chemical interfacing/scavenging with reactive oxygen and nitrogen species, (2) chemical modification of protein cysteines to persulfides, and (3) binding to and/or redox reactions with metal centers [7,20]. Additionally, H$_2$S may chemically reduce protein disulfides. The biochemical significance of this mechanism is currently unknown, and if it occurs, it is likely highly specific to the chemical milieu of the protein disulfide [40].

3. H$_2$S and Cancer

Recently, a complex and intricate role for H$_2$S has been identified in cancer. Below we discuss the role of H$_2$S in several common human malignancies and discuss the functions of H$_2$S in the initiation and promotion of cancer.

3.1. H$_2$S and Colorectal Cancer

Colon cancer is the second most lethal and third most common cancer worldwide [41]. The role of H$_2$S in cancer was demonstrated in 2013 when increased cytoplasmic and mitochondrial CBS expression was detected in seven colorectal carcinoma resections, compared to benign adjacent colonic tissues. CSE and 3-MST levels were unchanged. Several malignant colon cancer-derived cell lines similarly showed high CBS expression. Tumor tissue lysates incubated with L-cysteine and L-homocysteine also produced 6-fold more H$_2$S than lysates from benign tissue. CBS knockdown or pharmacologic inhibition by aminooxyacetic acid (AOAA) reduced cell proliferation and H$_2$S synthesis in the HCT116 colon cancer cell line, but not in the slower-growing nonmalignant NCM356 cell line. CSE knockdown or pharmacologic inhibition by DL-propargyl glycine (PAG) affected neither HCT116 cell proliferation nor H$_2$S synthesis. AOAA also suppressed the migration and invasion of HCT116 cells, while NaHS, an H$_2$S donor, enhanced these events [42]. Low to moderate concentrations (0.1–1 mM) of the CBS allosteric activator S-adenosyl-L-methionine also increased HCT116 cell proliferation, bioenergetics, and H$_2$S synthesis for up to twelve hours, an event not seen with CBS knockdown [42,43]. CBS knockdown or AOAA inhibition also attenuated mitochondrial function, suppressing basal respiration, ATP production, and the spare respiratory capacity. CBS knockdown similarly reduced glycolysis, in part through reduced glyceraldehyde 3-phosphate dehydrogenase (GAPDH) activity. Cystathionine failed to stimulate cell proliferation or cellular bioenergetics, indicating that H$_2$S and not cystathionine affected these cell behaviors. CBS, but not CSE knockdown, also significantly reduced the growth and volume of HCT116 cell xenografts in Nu/nu Balb/C female mice, with a concomitant reduction in CD31-immunopositive blood vessel density, the prevalence of larger blood vessels, and blood vessel branching. Additionally, the direct injection of AOAA into the xenograft tumor parenchyma reduced peritumor blood flow, while administration of the CBS substrate L-cysteine increased this flow [42,43].

Further studies revealed that premalignant colonic tubular adenomas (low-grade epithelial dysplasia) exhibited increased CBS expression, indicating that increased CBS expression is an early event in colon cancer [44]. Lentiviral vector-mediated CBS expression in the nonmalignant NCM356 colon cell line increased H$_2$S synthesis, reverse transsulfuration pathway flux, cell proliferation, migration, invasion, mitochondrial bioenergetics, and glycolysis. CBS expressing NCM356 cells also formed larger tumors in athymic nude mice compared to vector only bearing cells. Whole transcriptome RNA sequencing was employed to compare the CBS expressing NCM356 cells to those carrying the vector alone. CBS expression caused a metabolic shift towards anabolic metabolism, increasing the gene expression patterns related to glycolysis, hypoxic responses, extracellular matrix formation, cell adhesion molecule production, and epithelial to mesenchymal transition (EMT), resulting in a gene expression pattern that overlapped with an oncogenic phenotype [44]. These studies were extended when HCT116 cells were treated with 300 µM of the 3-MST inhibitor 2-[(4-hydroxy-6-methylpyrimidin-2-yl)sulfanyl]-1-(naphthalen-1-yl)ethan-
1-one (HMPSNE). HMPSNE suppressed 3-MST, CBS, the H$_2$S-degrading enzymes ethylmalonic encephalopathy 1 protein, and rhodanese expression, suggesting that 3-MST-derived (but not CBS/CSE-derived) H$_2$S exerts transcriptional regulatory actions in these cells [45]. HMPSNE treatment also increased mRNA and protein expression of the epithelial markers E-cadherin and tight junction protein ZO-1. Concomitantly, mRNAs for the mesenchymal markers fibronectin, Wnt3, β-catenin, and cadherin-associated protein β1, the transcription factors Snail1, Twist1, Sp1, and Sp3, and β-catenin, and both the ATP citrate lyase (ACLY) protein and mRNA expression were suppressed. ACLY is a key enzyme in acetyl-CoA synthesis associated with Wnt signaling and is implicated in the colon cancer EMT [45]. ACLY enzymatic activity was not induced by H$_2$S; however, H$_2$S partially reversed its inactivation by reactive oxygen species (ROS). Moreover, the slow H$_2$S donor GYY4137 activated the ACLY gene promotor through the induction of the Sp3 transcription factor. Lastly, HMPSNE treatment also attenuated cell migration, consistent with EMT inhibition [46]. Taken together, the above studies indicate that H$_2$S promotes the progression of colon cancer from preneoplastic low-grade dysplastic lesions to metastatic, dedifferentiated colon cancer.

The inhibition of H$_2$S synthesis increases the sensitivity colon cancer cells to chemotherapeutic agents, while chemotherapy resistance is associated with increased H$_2$S synthesis. For example, the treatment of the colon cancer cell lines HT-29 and DLD-1 with AOAA increased their sensitivity to 5-fluorouracil (5-FU), lowering cell colony formation, Bcl-2 expression, and viability, while increasing cell S-phase accumulation, apoptosis, cytochrome C release, and Bax expression. In a murine tumor xenograft model, DLD-1 cells stably over-expressing luciferase were injected into mice, allowing the bioluminescent noninvasive imaging of the cells. AOAA and 5-FU treatments in this model both lowered tumor growth, while the two combined synergistically suppressed tumor growth. AOAA also suppressed the target of 5-FU, thymidylate synthase. Further analysis revealed that CBS-synthesized H$_2$S suppressed the colon cancer tumor suppressor miR-215-5p, increasing both thymidylate synthase and epiregulin (an EGFR signaling activator) [47]. AOAA treatment also increased the sensitivity of the colon cancer cell line oxaliplatin, significantly reducing the IC$_{50}$ value, and GSH, Bcl-2, total caspase-9, and total caspase-3 expression, while increasing oxaliplatin-induced apoptosis, ROS levels, cleaved caspase-9, cleaved PARP, Bax, and p53 expression. In murine xenograft studies, AOAA and oxaliplatin reduced colon cancer cell growth, while the combination significantly reduced tumor volume compared to either agent alone [48].

In an interesting study, HCT116 cells were cultured for six months with increasing 5-FU concentrations in media maintained at 30 µM of 5-FU. When challenged with 3–100 µM of 5-FU, the parental cells exhibited lower viability and proliferation, while the 5-FU resistant cells showed no viability or proliferative changes. Western blot analyses revealed that CBS, 3-MST, and rhodanese increased by 49%, 63%, and 107% in the 5-FU resistant cells, with higher CBS and 3-MST enzymatic activities in these cells [49]. The 5-FU resistant cell line showed increased glutamate oxaloacetate transaminase and cytochromes p450 CYP1A2 and CYP2A6 expression. The p450 inhibitor phenylpyrrole sensitized the 5-FU resistant cells to 5-FU treatment, while the sensitivity of the parental cell line 5-FU was not increased by this treatment. Lastly, the 5-FU resistant cells were resistant to AOAA treatment, showing less viability and proliferation suppression than the parental cell line when treated with AOAA and 5-FU. Taken together, the above data indicate that increased CBS and 3-MST protein levels and enzymatic activities play a role in chemotherapy resistance [49]. The roles of CBS, 3-MST, and H$_2$S in colon cancer are summarized in Figure 1.
3.2. H2S and Ovarian Cancer

Ovarian cancer carries a 1.39% lifetime risk in women and due to its often-advanced stage at presentation, it is one of the most lethal gynecologic malignancies [50]. A tissue microarray analysis of 210 epithelial ovarian tumors revealed increased CBS expression compared to benign counterpart tissue. Moderate to strong CBS immunoreactivity was associated with a serous histology and a higher tumor grade, although significant expression was also seen in early-stage tumors. Additionally, of six ovarian tumor cell lines examined, four showed significant CBS protein and mRNA expression, while two showed high CSE expression compared to a benign epithelial ovarian cell line. CBS siRNA knockdown or AOAA treatment of the CBS-expressing ovarian cancer cells lines resulted in a significant suppression of cell proliferation (measured by 3H-thymine incorporation) and a lowered viability. CBS siRNA knockdown also resulted in a significant reduction in the total cellular GSH (GSH + GSSH) and increased RelA/p65 expression (a subunit of NF-κB), with concomitant increased ROS and p53 protein expression. Interestingly, culturing the cells in 5 mM Na2S resulted in a 20% increase in cell viability and culturing in 2 mM of GSH-containing media resulted in a complete recovery of cell viability, indicating a link between CBS-synthesized H2S, GSH levels, and cell viability. Lastly, siRNA CBS KD also increased the sensitivity of the ovarian cancer cell line to cisplatin, lowering the IC50 from 13.1 to 7.9 μM [51].

The A2780 ovarian cancer cell line showed both cytoplasmic and mitochondrial CBS expression. CBS knockdown in these cells significantly enhanced MitoSOX fluorescence, indicating increased superoxide. Additionally, citrate synthase activity was also decreased with increased AOAA concentrations, suggesting that CBS knockdown inhibited mitochondrial oxidative capacities. To confirm this, siRNA CBS knockdown and scrambled RNA (scRNA)-treated cell mitochondrial bioenergetics were analyzed [51]. CBS knockdown decreased both basal and maximally stimulated mitochondrial respiration. These changes were accompanied by an increase in the NAD/NADH and ADP/ATP ratios and ROS levels, and a decrease in total ATP [51]. Taken together, these data demonstrate a role of CBS in the maintenance and regulation of mitochondrial function in ovarian cancer [51].

To extend these observations, the mitochondrial fusion and fission apparatus proteins MFN1, MFN2, Drp1, OPA1, and Fis1 were examined in two ovarian cancer cell lines (CP20 and OV90) with scRNA or CBS siRNA knockdown [52]. Of the five proteins, only MFN2 expression was down-regulated by CBS knockdown. Interestingly, the Mitotracker Red CMXRos staining of these cells revealed that the scRNA cells had fused and elongated the mitochondrial morphology, while the siRNA CBS knockdown cells displayed a predominantly spherical mitochondrial morphology and more unbranched mitochondria with a shorter length. Additionally, CBS or MRN2 siRNA knockdown significantly lowered the mitochondrial oxygen consumption rate and the membrane potential, cell proliferation, ATP production, and spare respiratory capacity. The treatment of siRNA CBS knockdown cells with the slow H2S donor GYY4137 increased the mitochondrial oxygen consump-
tion rate, suggesting that CBS-generated metabolites regulate mitochondrial function. No changes in the autophagy markers or PGC1α were detected in the CBS knockdown cells. Similarly, the mitochondrial genome number did not change with CBS knockdown. Based on this, it was concluded that CBS knockdown induced mitochondrial fragmentation, but not autophagy by MFN2 suppression. Additionally, CBS maintained mitochondrial health through promoting fusion, ATP synthesis, and MFN2 stabilization [52].

CBS silencing did not affect MRN1 or MRN2 mRNA expression. Immunoprecipitation analyses revealed that CBS silencing increased MFN2 ubiquitination, resulting in its destabilization and degradation. Support for this came from the observation that treatment with the proteasome inhibitor MG132 rescued MFN2 expression with CBS silencing. The JNK kinase is activated by oxidative stress, resulting in its phosphorylation of MFN2, followed by MFN2 ubiquitination. Treatment of CBS silenced cells with either the antioxidant mitoTEMPO or the JNK inhibitor SP600125 rescued MFN2 expression [52]. Thus, CBS maintains mitochondrial function by attenuating ROS levels, an event required to preserved MFN2 protein expression [52]. The clinical relevance of CBS and MFN2 expression in ovarian cancer was examined in the clinically annotated mRNA data from The Cancer Genome Atlas (Gene Expression Omnibus) databases. In the quantitative analysis for Kaplan–Meier overall survival curves, a high expression of CBS and MFN2 conferred a poor overall survival of patients, with CBS and MFN2 expression showing a significant association in the same patient cohort [52].

The effects of CBS expression on tumor growth were examined in a previously developed murine orthotopic model of ovarian cancer. Mice were interperitoneally injected with the ovarian A2780 tumor cell line and after one week the mice were injected with neutral liposomes containing either control siRNA or CBS siRNA twice weekly, with or without cisplatin [52]. After four weeks the mice were sacrificed, and the tumors were analyzed. The mice receiving the CBS siRNA had a 40% lower tumor weight, a 70% reduction in tumor nodules, and lower proliferation and blood vessel formation, as measured by Ki-67 and CD31 immunostaining, respectively [52]. Interestingly, with cisplatin, the siRNA treated mice showed a small and nonsignificant reduction in tumor weight, while the mice treated with CBS siRNA plus cisplatin exhibited a 90% reduction in tumor weight compared to the mice treated with siRNA only [51]. The roles of CBS and H2S in ovarian cancer are summarized in Figure 2.

![Figure 2](image-url)  

Figure 2. A summary of the roles of CBS and H2S in ovarian cancer growth, progression, metastasis, mitochondrial, function, and chemotherapy resistance. O2− is the superoxide radical [51].
3.3. Breast Cancer

Breast cancer is the most common cause of cancer death in women worldwide [53]. A tissue microarray was employed to analyze CBS expression in 60 breast cancer cases compared to adjacent benign tissue. CBS expression was significantly increased in breast cancer, and increased further with higher breast cancer stages, with the highest expression in metastatic disease. CBS mRNA and protein levels were also higher in breast cancer cell lines compared to benign mammary epithelial cells, with the cancer cell lines producing 2 to 4-fold more \( \text{H}_2\text{S} \) and 64-fold more cystathionine than the benign cells. CBS knockdown in the breast cancer cell lines lowered \( \text{H}_2\text{S} \) and cystathionine synthesis, but not cell growth in culture [54].

CBS knockdown accompanied by co-culture with activated macrophages caused significant cell growth suppression. Additionally, following three weeks growth in murine xenograft models, CBS siRNA knockdown in breast cancer cells resulted in lower tumor volumes compared to cells without knockdown (8 mm\(^2\) vs. 125 mm\(^2\)). Lentiviral-mediated increased CBS expression in breast cell lines that expressed undetectable CBS levels caused a 4.5-fold increase in \( \text{H}_2\text{S} \) synthesis, easily detected CBS protein, and no growth suppression when co-cultured with activated macrophages (something seen without increased CBS). CBS knockdown and co-culture with activated macrophages increased the levels of the 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) breast cancer cell lines. Co-incubation with the slow-releasing \( \text{H}_2\text{S} \) donor GY4137 reduced 4-HNE and MDA levels by 40–50% and increased cell growth by 60–80%. Cell fractionation experiments revealed that CBS localized to the breast cancer cell membrane, demonstrating that CBS conferred resistance to macrophage-generated ROS by plasma membrane \( \text{H}_2\text{S} \) synthesis [55]. Interestingly, cystathionine is also highly enriched in breast cancer due to high CBS expression. Cystathionine has been shown to protect breast cancer cells from ROS-induced damage, chemotherapy-induced apoptosis, and promote mitochondrial and endoplasmic reticulum homeostasis in breast cancer cells. Thus, CBS may also promote breast cancer via the production of this cancer-protective oncometabolite [54].

Similarly, CSE expression was analyzed in 15 breast cancer cases and compared to benign adjacent tissues. CSE mRNA and protein levels were increased in breast cancer compared to benign tissue and increased in breast cancer cell lines compared to a benign mammary epithelial cell line. siRNA CSE knockdown in MCF7 breast cancer cells lowered \( \text{H}_2\text{S} \) synthesis, cell proliferation, EdU incorporation, and cell migration, while increasing apoptosis and S phase cell arrest. CSE overexpression increased \( \text{H}_2\text{S} \) synthesis, EdU incorporation, and cell migration. Stat3 knockdown inhibited cell proliferation and migration, while increased Stat3 expression enhanced these capacities. An analysis of the CSE promoter demonstrated that phospho-Stat3 binds to the CSE promoter and increases CSE protein expression [56].

High breast cancer CSE promotes breast cancer metastasis. A separate analysis of 30 breast cancer cases revealed that CSE was: (1) higher in breast cancer than adjacent benign breast tissue, (2) increased in stage III cancers compared to stage II, (3) highest in metastatic disease, and (4) higher in ER, PR, and HER2/Neu immunonegative tumors (triple negative/basaloid breast cancer). Interestingly, triple negative breast cancer has a high recurrence and metastasis risk [57]. In the MBA-MB-231 breast cancer cell line, siRNA CSE knockdown reduced cell migration, invasion, and proliferation, while CSE overexpression enhanced these events. When MBA-MB-231 cells were injected into the tail veins of nude mice and lungs subsequently histologically examined four weeks later, a 75% pulmonary metastasis rate was seen. However, the metastatic rate was 12.5% with CSE knockdown. CSE knockdown in these cells also lowered the expression of angiogenesis and metastasis-associated/promoting proteins, including MMP-2, MMP-9, PIK-3, Akt, p-Akt, Ras, Raf, ERK1/2, phospho-ERK1/2, FAK, paxillin, and the vascular endothelial growth factor, while increased CSE expression increased the expression of these proteins [58]. Not surprisingly, a recently developed CSE inhibitor, I194496, lowered animal model metastases, while lowering the expression of the proteins listed above [59]. Taken together, these data
indicate that CBS and CSE are increased in breast cancer and play a significant role in breast cancer development, progression, and metastasis. The roles of CBS, CSE, and H2S in breast cancer are summarized in Figure 3.

![Figure 3. A summary of the roles of CBS, CSE, and H2S in breast cancer growth, progression, metastasis, chemotherapy resistance, and resistance to macrophage-generated ROS [54–59].](image)

### 3.4. Bladder Cancer

Bladder cancer is the 10th most common cancer worldwide, with the highest rates found in Europe, Australia, and North America, and it causes approximately 115,000 deaths each year [60]. In 94 patients who had had undergone a transurethral resection or a radical cystectomy for urothelial bladder cancer (UBC) all showed moderate to strong immunoreactivity for CBS, CSE, and 3-MST in the UBC, compared to little or no staining in a benign urothelium. The expression levels and the production of H2S in UBC tumor lysates increased with an increase in the tumor grade and stage [61]. Exogenous H2S also significantly increased cell proliferation and invasion, and MMP-2 and MMP-9 protein expression in the EJ human bladder cancer cell line. These events were increased with higher exogenous H2S dosages, suggesting that H2S increases the proliferative, invasive, and metastatic capacities of UBC [62].

### 3.5. Renal Cancer

Clear cell renal carcinoma (ccRCC) accounts for ~2.4% of malignancies and is characterized by a Von Hippel–Lindau protein (VHL)-deficiency, resulting in pseudohypoxic, glycolytic tumors [63]. A comparison of two VHL-deficient ccRCC cell lines (769-P and 786-O cells) to a VHL-wild-type ccRCC cell line and benign HK-2 renal cells revealed significantly higher H2S synthesis in the 769-P and 786-O cells. Although the levels of CBS, CSE, and 3-MST were the same in the different cells, enzyme inhibition preferentially suppressed the proliferation, metabolism, and survival of VHL-deficient ccRCC cell lines. Last, the systemic inhibition of H2S synthesis in a chorioallantoic membrane angiogenesis model significantly decreased vascularization in the VHL-deficient ccRCC cell xenografts. Taken together, these data support the idea that VHL loss results in pseudohypoxia and low mitochondrial oxidation, hence a low mitochondrial H2S catabolism, and subsequent increased cellular H2S [64].

In a tissue microarray study of 21 benign renal cortex and 94 ccRCC samples, CBS showed increasing expression in ccRCC Fuhrman grades II–IV. Thus, CBS expression may play a role in ccRCC progression [65]. Interestingly, in a study of 21 ccRCC tissue samples compared to benign renal tissues from the same individuals, 66% of the pair samples showed stable CBS expression, with the remaining samples exhibiting suppressed tumor tissue CBS levels. CSE expression was suppressed in all but three of the tumors compared to benign tissue, and 3-MST was suppressed in 70% of the tumors and was
unchanged in 30% of the tumors compared to benign tissue. The authors concluded that the H$_2$S-synthesizing enzymes showed varying expression in ccRCC [66]. The reason for this difference may lie in the fact that first study employing microarray technology did not compare benign/malignant tissues from the same patients [66].

3.6. Prostate Cancer

Prostate cancer is the most common male cancer in the US and is the 6th leading cause of male death worldwide [67]. In an elegant study, human PC3 prostate cancer cells were injected into the ventral prostate of male nude mice and allowed to grow for 40 days. Tumor cells were then isolated from the prostate and bone marrow, with the later representing metastatic disease. Seven sets of prostate/bone marrow metastatic PC3-derived cells were analyzed by microarray. CSE, but not CBS or 3-MST, was up-regulated in five of the metastatic cells vs. the cell pairs localized to the prostate. Two of these cell sets were further analyzed and the metastatic cells showed increased migration and invasive capacities, but a similar proliferation and similar GSH levels. The overexpression of CSE in the PC3 cells increased cellular H$_2$S levels, migration, and invasion, while siRNA knockdown suppressed these events. Interestingly, the treatment of the cells with the irreversible CSE inhibitor PAG substantially reduced invasion, but not cell migration, raising the possibility that CSE enzymatic activity is only required for cell invasion. To explore this possibility, a CSE mutant with low enzymatic activity was generated (CSE$^{Q240E}$) which had a decreased kinetic activity of ~70-fold. Cells carrying this mutation still exhibited cell migration but minimal invasion, indicating that CSE promotes cell migration by an enzymatic activity-independent mechanism [68].

To analyze human prostatic cancer CSE expression, 105 prostate tumors vs. 11 benign prostatic tissue samples were analyzed by microarray technology. CSE expression was significantly greater in stage III/IV prostate cancer than in stages I/II or adjacent non-tumor tissue. Patient survival and CSE expression was then correlated by using the TCGA PC RNA-seq dataset containing 469 prostate cancers and 50 benign tissue samples. CSE expression was higher in prostate cancer and at the eight-year follow-up, a significant correlation between high CSE levels and poor patient survival was identified. A similar association between CSE expression and poor survival was also identified in pancreatic adenocarcinoma and lower grade gliomas, implying a role for CSE in the progression of other cancer types [68].

Incongruously, in another study comparing prostate tumors and benign prostatic tissue, CBS expression was not changed, 3-MST was not detected, and CSE expression was lower in prostatic cancer. CSE expression was also lower in the prostatic tissue of aged mice compared to younger mice and was accompanied by a concomitant increase in proliferating cell nuclear antigen (PCNA) and cyclin D1 levels. Older CSE knockout mice also showed even higher PCNA levels. CSE expression was also lowered in prostatic cancer cell lines following antiandrogen-resistance development. Last, H$_2$S treatment inhibited the binding of the androgen receptor to the prostate-specific antigen (PSA) and the androgen-responsive element due to the post-translational androgen receptor S-sulfhydration inhibiting the binding of the androgen receptor [69].

3.7. Thyroid

Thyroid cancer constitutes approximately 1% of human malignancies, making it the most common of the neuroendocrine malignancies. Approximately 85% of thyroid cancers are the well-differentiated papillary (PC) and follicular carcinoma (FC) subtypes. The few remaining common subtypes are anaplastic thyroid (AC) and medullary thyroid carcinomas (MC) [70]. A tissue microarray analysis revealed that CBS expression is increased in PC, FC, MC, and ACs, but not in benign thyroid follicular adenomas [71]. In another study CSE, but not CBS or 3-MST expression, was increased in thyroid PC. PC CSE levels were significantly increased with an increased tumor size, extrathyroidal extension, and with lymph node metastases, but not with patient gender, age, or tumor stage. Interestingly,
sonic hedgehog signaling pathway molecules, sonic hedgehog, patched, and smoothened were also increased on PC, with significant increases seen in the same parameters as for CSE, suggesting interactions between CSE and the sonic hedgehog pathways [72]. The reasons for the differences in CBS and CSE expression in thyroid cancer shown in these studies likely lie in the different patient populations analyzed and the different experimental techniques used.

In a comparison of a benign human thyroid cell line to thyroid cancer cell lines, 25–50 µM NaHS increased CBS, sulfide:quinone oxidoreductase, p-PI3K, p-AKT, p-mTOR, H-RAS, p-RAF, p-MEK1/2, and p-ERK1/2, and rhodanese protein expression, while enhancing cell proliferation, migration, and viability in the cancer, but not benign cell lines. All of these events were inhibited by 200 µM NaHS in the cancer cell lines [73]. Furthermore, 1.4–2.8 mg/kg/day NaHS promoted tumor growth and blood vessel formation in human thyroid carcinoma xenograft tumors models, while 11.2 mg/kg/day NaHS inhibited these events. In summary, this study demonstrated that: (1) the ROS/PI3K/Akt/mTOR and RAS/RAF/MEK/ERK signaling pathways function in conjunction with H\(_2\)S to promote thyroid cancer cell growth and (2) H\(_2\)S exerts cancer cell growth-promoting or -inhibiting effects depending on the dosage [73].

3.8. Pulmonary Adenocarcinoma

An analysis of 20 pulmonary adenocarcinomas and benign matched lung tissue samples showed increased H\(_2\)S levels and increased CBS, CSE, and 3-MST in the malignant tissue. Similar results were also found in three lung cancer adenocarcinoma cell lines (A549, NCI-H522, and NCI-H1944 cells) compared to nonmalignant lung epithelial cells (BEAS 2B cells). An analysis of mitochondrial DNA (mtDNA) stability in the lung cancer and adjacent benign lung tissue revealed that the tumor mtDNA had significantly fewer DNA breaks and a higher mtDNA copy number. The same analysis of the lung cancer and BEAS 2B cells revealed higher DNA damage in the lung cancer cells. A MitoSOX analysis of the A549, NCI-H522, and BEAS 2B cells revealed higher ROS in the tumor cells. A549 cell treatment with AOAA or siRNA knockdown of CBS, CSE, or 3-MST in the presence of mild chronic oxidative stress increased mtDNA breaks, an event blocked by the mitochondrial-specific H\(_2\)S donor AP39. Incubation with serine or homocysteine for 24 h resulted in no changes in mtDNA breaks, ruling out their accumulation as a mechanism of changes in mtDNA breaks [74].

To further these studies, the mitochondrial-specific DNA repair enzyme EXOG which forms complexes with APE1, PolG, and Lig3 was analyzed by proximity ligation assay with and without 300 µM of AOAA treatment in A549 cells. AOAA significantly reduced the complex formation, while simultaneous treatment with AP39 restored the complex formation. Mass spectrometric analysis of EXOG revealed that EXOG Cys 76 was post-translationally sulfhydrated by oxidized H\(_2\)S metabolites. Co-immunoprecipitation assays with wild-type and mutant EXOG C76A with APE1 showed that Cys 76 was required for the EXOG/APE1 complex formation, and the complex formation was enhanced by cell NaHS treatment. This NaHS-induced enhancement was not seen with the mutant EXOG C76A. These data indicate that H\(_2\)S plays a central role in lung cancer mitochondrial DNA repair [74]. Similar to other studies, the inhibition of H\(_2\)S synthesis in the A549 cells, but not the BEAS 2B cells, reduced all major mitochondrial bioenergetic parameters. This reduction was rescued by AP39 treatment in the A549 cells. Lastly, in a murine xenograft model, A549 cells showed reduced growth with AOAA or irinotecan treatment, and significantly reduced tumor growth with both treatments, demonstrating that H\(_2\)S synthesis inhibition potentiated the tumor-suppressing effects of this chemotherapy agent [74].

3.9. Melanoma

Melanoma is the deadliest skin cancer and the 19th most common cancer worldwide [75]. In a study of six compound nevi, four junctional nevi, and four dysplastic nevi, all were positive for CSE, variably positive for 3-MST, and negative for CBS. An analysis
of one normal human epidermal melanocytic (NHEM) cell line and four melanoma cell lines showed a very low expression of all three enzymes in the NHEM cell line, with the melanoma cell lines showing mildly increased CSE, and no changes in CBS and 3-MST expression. CSE overexpression in the melanoma cell line with the lowest CSE expression (A375 cells), inhibited cell proliferation by 30%. CBS and 3-MST overexpression had no effect [76].

Garlic (*Allium sativum*) has a long history of medicinal use and contains several H\textsubscript{2}S-donating compounds, such as diallyl trisulfide (DATS) [77,78]. DATS, similar to the H\textsubscript{2}S donor GYY4137, releases H\textsubscript{2}S relatively slowly, while H\textsubscript{2}S donors such as Na\textsubscript{2}S and NaHS instantaneously disassociate in solution, releasing H\textsubscript{2}S very rapidly, unlike the slower, steady-state H\textsubscript{2}S production by the three H\textsubscript{2}S-synthesizing enzymes [79]. Since an increased CSE expression inhibited cell proliferation, the melanoma cell line was treated with DATS and GYY4137 to examine the effects of slow H\textsubscript{2}S release on melanoma cell line viability [76]. Treatment of the A375 cell line with these H\textsubscript{2}S donors inhibited proliferation, induced apoptosis, and caused a G\textsubscript{0}/G\textsubscript{1} phase arrest [76].

Melanoma growth is partially dependent on constitutive NF-\kappaB activation and pro-motor binding [80]. Interestingly, DATS and GYY4137 treatment inhibited NF-\kappaB DNA binding and anti-apoptotic gene expression via the inhibition of I\kappaB\alpha degradation. Similarly, treatment with these H\textsubscript{2}S donors reduced the expression of the melanoma cell lines p-AKT and p-ERK. Lastly, in a murine xenograft melanoma animal model, subcutaneously injected melanoma cells exhibited a 51% growth reduction with the oral administration of the CSE substrate L-cysteine. This effect was negated by the oral co-administration of the CSE inhibitor PAG. Taken together, these data indicate that CSE exerts inhibitory effects on melanoma growth through the inhibition of NF-\kappaB and the growth-promoting signal transduction pathway [76].

### 3.10. Oral Squamous Cell Carcinoma

Head and neck cancers are the 6th most common malignancies worldwide, and 70% are squamous cells carcinomas (SCC) [81]. The comparison of 15 oral SCCs to adjacent benign tissue revealed a roughly 3-fold increase in CBS, CSE, and 3-MST in the SCC. Increased Stat3, p-Stat3, MitoNEET, nicotinamide phosphoribosyl transferase, hTERT, and MAPK were also identified. It is interesting that increased p-Stat3 was identified in SCC, as this transcription factor increases CSE expression in breast cancer [56]. SCC and adjacent benign H\textsubscript{2}S concentrations were measured directly by an immediate punch biopsy followed by quick-freezing in liquid N\textsubscript{2} and H\textsubscript{2}S analysis by the monobromobimane method coupled with reverse phase-HPLC [29]. H\textsubscript{2}S concentrations were significantly (~13%) increased in the SCC compared to the adjacent benign tissue [16]. Although H\textsubscript{2}S-synthezing enzymatic activities were not measured, the 3-fold increased expression of all three enzymes suggests that tumor H\textsubscript{2}S synthesis was much higher than 13%. Thus, tumor synthesized H\textsubscript{2}S is likely being transferred to other portions of the sulfur pool, contributing to oncogenesis [36].

### 4. Protein Sulphhydration and Cancer

Protein sulphhydration is a post-translational protein modification where a sulfur atom is added to a reactive protein cysteine, forming an -SSH or a persulfide group. The cysteine persulfide formation involves an oxidized cysteine derivative reacting with a sulfide or sulfide oxidation products. Protein sulphhydration exerts predominately inhibitory effects, with most activating events due to the persulfidation-induced inhibition of a negative regulator [7]. Here we will review several well characterized cancer-related sulphhydrated proteins.

#### 4.1. NF-\kappaB

NF-\kappaB is a family of dimeric transcription factors that are activated by a large number of stimuli and play an important role in immune responses, inflammation, and cancer [82]. In the prostate cancer PC3 cell line, NaSH treatment increased cell invasion and NF-\kappaB p65
cysteine 39 sulfhydration, as measured by a modified biotin switch assay. Maximal p65 cysteine 39 sulfhydration was seen at NaSH concentrations of 10 nM to 10 µM, indicating that the sulfhydration occurred at physiologically relevant donor concentrations [82]. Conversely, CSE knockdown decreased this sulfhydration and cell invasion. PC3 cells with p65C38S mutant expression exhibited attenuated NaSH-induced invasive capacities and abolished sulfhydration. The re-expression of wild-type p65 expression rescued these events. In a murine xenograft animal model, the p65C38S mutant showed significantly fewer metastases than wild-type p65. Taken together, these data indicate that the sulfhydration of the p65 subunit Cys plays a central role in promoting prostate cancer metastasis [68].

4.2. GAPDH

The sulfhydration of GAPDH cysteine 150 was measured by a biotin switch assay. While wild-type CSE elicited GAPDH sulfhydration, the catalytically inactive mutant CSE did not. Similarly, GAPDH sulfhydration was identified in the livers of CSE wild-type, but not CSE knockout mice. The treatment of HEK293 with NaHS over a 3 to 100 µM concentration increased GAPDH enzymatic activity by up to 700% [83]. As this is a high concentration of a fast H2S releasing donor, the physiological significance of this event requires further study, ideally with a lower concentration of a slow-releasing H2S donor. A role for GAPDH in cancer comes from the observation that CBS knockdown in colon cancer cell lines lowers GAPDH enzymatic activity [42].

4.3. Lactate Dehydrogenase (LDHA)

LDHA converts pyruvate to lactate and is increased in colon cancer, where it contributes to tumor proliferation and bioenergetics. Treatment of HCT116 cells with GYY4137 increases mitochondrial function and glycolysis in these cells. GYY4137 treatment increases LDHA cysteine 163 sulfhydration, increasing its activity. GYY4137 treatment did not increase LDHA activity with the LDHA C163A mutation. GYY4137 treatment also increased the total cellular lactate with wild-type LDHA expression, but not with LDHA C163A expression. Last, LDHA C163A expression increased cellular sensitivity to ROS. Based on these results, it was concluded that the sulfhydration of LDHA cysteine 163 plays a role in H2S-promoting colon cancer [84].

The number of sulfhydrated proteins in cancer is rapidly growing and there are far more than the ones listed above. Undoubtedly, this area of research will grow and many more sulfhydrated proteins that are important in cancer will be identified.

5. Polysulfides and Cancer

High CBS and CSE expression confer a poor prognosis in ovarian cancer [36,52]. Surface-enhanced Raman spectroscopy of 186 stage III or IV ovarian cancers indicated that high CSE expression correlated with a poor prognosis, tumor cisplatin resistance, and increased tumor polysulfides. Similarly, high CSE expression in ovarian tumor cell lines increased cisplatin resistance due to increased polysulfide synthesis. CSE knockdown increased the sensitivity of ovarian tumor cells to cisplatin and was accompanied by a concomitant increase in histone H2AX phosphorylation and decreased polysulfides. In in vitro experiments hydrogen polysulfides reduced cisplatin-induced DNA damage, with less damage seen with increasing sulfur atom numbers in each polysulfide [36]. Interestingly, the tumor suppressor gene product PTEN is inactivated by polysulfides where sulfane sulfur is added to an active site cysteine, ablating PTEN phosphatase activity [85]. It is likely that this and many other polysulfide-related events play an under-appreciated role in cancer.

6. H2S-Associated Tumor Markers in Bodily Gas and Fluids

Multiple studies have shown increased H2S and related sulfur compounds in cancer patients compared to control subjects. For example, increased H2S occurs in the headspace vapor of gastric contents in patients with gastro-esophageal cancer, while increased H2S
and methanethiol were identified in the flatulence and exhaled air of colon and lung cancer patients [86–88]. In men with prostate cancer, urine thiosulfate concentrations were 50-fold higher than men without cancer, suggesting that urine thiosulfate may have diagnostic value for prostatic cancer in men with low PSA and negative digital rectal exams. Men with benign prostatic hypertrophy had only a 5-fold increase in urine thiosulfate, differentiating hypertrophy from cancer [89]. Cysteine, homocysteine, and cystathione were also elevated in the urine of men with recurrent prostate cancer, while urine cystathionine and sarcosine concentrations correlated with prostate cancer stage [90–92]. High plasma homocysteine levels have been identified in individuals with several malignancies, including endometrial, esophageal, SCC, prostate, colorectal, and breast cancers [93]. Lastly, endogenous H$_2$S has been used as a cancer biomarker and as a way to detect cancer cells in mice [94,95]. These studies indicate that H$_2$S and related sulfur compounds can be elevated in bodily gas and fluids and may have utility in cancer diagnostics. Specifically, H$_2$S and related sulfur compounds could be used in cancer detection through the measurement of compounds such as plasma and urine thiols, or employed to monitor the effectiveness of cancer treatment, remission induction, and the early detection of recurrence.

7. H$_2$S and Nuclear DNA Repair

Recently, a role for H$_2$S in DNA repair has been identified, where ATR kinase inhibition resulted in lower cellular H$_2$S levels. Low cellular H$_2$S concentrations increased ATR kinase activity measured by CHK1 phosphorylation, while high H$_2$S concentrations suppressed ATR ser-435 phosphorylation, a marker of ATR kinase activation [4,96]. Increased ATR-CHK1 pathway activity has been identified in several tumor types [97–100]. Additionally, increased ATR protein, phospho-ATR, and phospho-CHK1 expression confers a poor prognosis in breast, bladder, and ovarian cancers [98–100]. As the ATR kinase regulates H$_2$S concentrations, it is possible that increases in ATR and CHK1 result in increased H$_2$S synthesis. Additionally, targeted ATR inhibition is now being explored in cancer therapy [101]. Possibly, this cancer therapy approach may work, in part, through the suppression of H$_2$S synthesis [95]. These possible cancer-related events should be explored.

8. The Immunomodulatory Role of H$_2$S in Cancer

H$_2$S exerts complex and powerful immune system modulating effects in both normal and pathologic conditions, often showing impaired functions at very low and high H$_2$S concentrations [102]. Presently, there is some evidence that H$_2$S-induced immune modulation plays a role in cancer [55]. As previously discussed, in breast cancer CBS localizes to the cancer cell membrane, where CBS-derived H$_2$S protects the cancer cells from activated macrophage-generated ROS [55]. Additionally, in an interesting study melanoma cell-bearing mice were injected with a vehicle or the vehicle with DATS and analyzed for melanoma growth, splenic myeloid-derived suppressor cells (MDSCs), dendritic cells, and T cells [103]. The MDSCs function by suppressing tumor-specific T lymphocytes, contributing to malignant progression. DATS injection inhibited melanoma growth and lowered the frequency of splenic, blood, and tumor micro-environment MDSCs, while increasing CD8 T cells and dendritic cells. DATS treatment also significantly reduced the immune-suppressive activity of the MDSCs, restoring T cell function and T cell-mediated tumor growth suppression, demonstrating that H$_2$S donation modulates tumor growth through immune system regulation [103]. These studies indicate that H$_2$S can both enhance and suppress tumor growth through immune system modulation.

9. Conclusions, Issues, and Future Directions

The summary presented here is incomplete due to the enormous body of research on H$_2$S and cancer, where H$_2$S promotes a plethora of cancer-related effects (vide supra, summarized in Table 1 and Figures 1–4). Several areas in this research should be addressed, while other promising results require further examination.
### Table 1. A summary of the expression patterns of CBS, CSE, and 3-MST in several different human malignancies and synopses of the findings.

| Tumor Type                  | H2S Synthesizing Enzyme Expression | Comments                                                                                                                                                                                                 | References |
|-----------------------------|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Colon Cancer                | CBS increased                     | Higher colon cancer CBS promotes cancer growth, mitochondrial bioenergetic activity, and increased glycolysis, migration, invasion, and chemotherapy resistance. While not increased, 3-MST expression promotes colon cancer EMT. | [42,43,48,49] |
| Ovarian Cancer              | CBS and CSE increased             | Increased CBS and CSE promote events including cancer growth, more active mitochondrial bioenergetics and morphologic integrity, migration, invasion, chemotherapy resistance, and a poor prognosis. Data also indicates a role for polysulfides in ovarian cancer. | [36,51,52]  |
| Breast Cancer               | CBS and CSE increased             | Increased CBS and CSE promote cell growth, migration, and chemotherapy resistance. Membranous CBS protects cells from macrophage-derived ROS and confers a worse prognosis. CSE promotes breast cancer metastasis. | [39,56,58]  |
| Bladder Cancer              | CBS, CSE, and 3-MST increased     | H2S likely promotes bladder cancer cell proliferation and invasion, and MMP-2 and MMP-9 protein expression. H2S synthesis in tumor lysates positively correlates with tumor stage and grade. | [61,62]    |
| Renal Cancer                | Most studies show suppressed or unchanged expression | H2S appears to promote tumor growth. The present studies show contradictory results, possibly based on analysis methods employed. | [64–66]    |
| Prostate Cancer             | Increased or decreased CSE in different studies | CSE promotes cell proliferation, migration, invasion, and poor patient survival. CSE promotes cell migration by an enzymatic activity-independent mechanism. Another study shows that CSE suppression promotes prostatic cancer. | [68,69]    |
| Thyroid Cancer              | CBS and CSE increased             | Different studies show increased CBS or CSE. NaHS promotes thyroid cancer proliferation, migration, and cell viability.                                                                                   | [71–73]    |
| Pulmonary adenocarcinoma    | CBS, CSE, and 3-MST increased     | H2S promotes cell proliferation, mitochondrial bioenergetics, and mitochondrial DNA repair.                                                                                                                 | [74]       |
| Melanoma                    | Mildly increased CSE expression   | CSE expression inhibited melanoma cell growth and H2S donors increased apoptosis by NF-κB inhibition.                                                                                                        | [76]       |
| Oral squamous cell carcinoma| CBS, CSE, and 3-MST increased     | Direct measurements of tumor H2S concentrations revealed 13% higher H2S than in adjacent benign oral squamous epithelium.                                                                                     | [16]       |
First, many of the pharmacologic tools used in H$_2$S research have flaws. For example, while AOAA is commonly used as a CBS inhibitor, it also inhibits CSE, 3-MST and over thirty other cellular enzymes, greatly complicating the experimental results [104]. Similar sub-optimal specificity is seen with many other H$_2$S synthesizing enzyme inhibitors, such as β-cyano-alanine [105]. The commonly used pharmacologic H$_2$S donors, Na$_2$S and NaHS, also very rapidly disassociate in solution, likely resulting in high transient, non-physiologic H$_2$S concentrations which do not reflect normal or even pathologic conditions [105]. Thus, advancing H$_2$S research necessitates the development of more specific H$_2$S-synthesizing enzyme inhibitors and the use of slow-release H$_2$S donors that better reflect the slow and steady H$_2$S enzymatic synthesis [96,105].

Secondly, an under researched area is the functional differences between the H$_2$S synthesizing enzymes. For example, mutant CSE in prostate cancer cells resulted in low cellular invasive capacities, but did not affect cell migration, showing that the CSE-generated H$_2$S was only one aspect of CSE-initiated activities [68]. Careful analysis of the functions of the H$_2$S-synthesizing enzymes, including the mutation of different portions of the enzymes, should elucidate exactly what role each portion of the enzymes has in regulating cellular functions and in promoting cancer.

Third, polysulfides are a new and exciting area of cellular biology [18]. Presently there are several papers showing a role for polysulfides in cancer [36,85]. Undoubtedly, further research will show that polysulfides play an important and underappreciated role in cancer. Fourth, epigenetics plays a major role in cancer [106]. Presently, there are no data on H$_2$S cancer epigenetics. It is very likely that in cancer, H$_2$S will alter the epigenome in the promotion of cancer.

Lastly, while not covered in this review, targeted therapies directed towards H$_2$S metabolism in cancer are a promising area in cancer treatment [96,107]. H$_2$S synthesis inhibition and H$_2$S donators have been shown to induce cancer cell death, while often sparing benign cells. Both of these processes are currently being explored, with and without concomitant chemotherapy [73,96,107]. A better understanding of the role of H$_2$S in cancer will undoubtedly facilitate the development of better cancer therapies.

**Author Contributions:** R.E.S., C.G.K., A.T.M. and G.E.G. contributed to the research and writing of this manuscript. D.K., I.Z.M., S.P. and F.A. did most of the literature search and helped with...
assembling the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by grants from The A-T Children’s Project and an intramural research support grant from Louisiana Health Sciences Shreveport, from the Center for Cardiovascular Diseases and Sciences. Lastly, this work was supported by an Institutional Development Award (IDeA) from the National Institutes of General Medical Sciences of the NIH under grant number GM121307 and HL149264 from the National Heart, Lung, and Blood Institute to C.G.K.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We would like to thank Lis Lachance, for her help in the assembly and proof-reading of this manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Reiffenstein, R.J.; Hulbert, W.C.; Roth, S.H. Toxicology of hydrogen sulfide. *Annu. Rev. Pharmacol. Toxocol.* 1992, 32, 109–134. [CrossRef] [PubMed]
2. Nicholson, R.A.; Roth, S.H.; Zhang, A.; Brookes, J.; Skrauty, B.; Bennington, R. Inhibition of respiratory and bioenergetic mechanisms by hydrogen sulfide in mammalian brain. *J. Toxicol. Environ. Health A* 1998, 54, 491–507.
3. Warenycia, M.W.; Smith, K.A.; Blashko, C.S.; Kombian, S.B.; Reiffenstein, R.J. Monoamine oxidase inhibition as a sequel of hydrogen sulfide intoxication: Increases in brain catecholamine and 5-hydroxytryptamine levels. *Arch. Toxicol.* 1989, 63, 131–136. [CrossRef] [PubMed]
4. Chen, J.; Shen, X.; Pardue, S.; Meram, A.T.; Rajendran, S.; Ghali, G.; Kevil, C.G.; Shackelford, R.E. The Ataxia telangiectasia-mutated and Rad3-related protein kinase regulates cellular hydrogen sulfide concentrations. *DNA Repair* 2019, 73, 55–63. [CrossRef] [PubMed]
5. Abe, K.; Kimura, H. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J. Neurosci.* 1996, 16, 1066–1071. [CrossRef] [PubMed]
6. Wang, R. Two’s company, three’s a crowd: Can H$_2$S be the third endogenous gaseous transmitter? *FASEB J.* 2002, 16, 1792–1798. [CrossRef]
7. Nagy, P. Mechanistic chemical perspective of hydrogen sulfide signaling. *Methods Enzymol.* 2015, 554, 3–29.
8. Geng, B.; Yang, J.; Qi, Y.; Zhao, J.; Pang, Y.; Du, J.; Tang, C. H$_2$S generated by heart in rat and its effects on cardiac function. *Biochem. Biophys. Res. Commun.* 2004, 313, 362–368. [CrossRef] [PubMed]
9. Fu, Z.; Liu, X.; Geng, B.; Fang, L.; Tang, C. Hydrogen sulfide protects rat lung from ischemia-reperfusion injury. *Life Sci.* 2008, 82, 1196–1202. [CrossRef]
10. Distruiti, E.; Sediari, L.; Mencarelli, A.; Renga, B.; Oltandi, S.; Antonelli, E.; Roviezzo, F.; Morelli, A.; Cirino, G.; Wallace, J.L.; et al. Evidence that hydrogen sulfide exerts antiinflammatory effects on the gastrointestinal tract by activating KATP channels. *J. Pharmacol. Exp. Ther.* 2006, 316, 325–335. [CrossRef] [PubMed]
11. Wang, Y.; Zhao, X.; Jin, H.; Wei, H.; Li, W.; Bu, D.; Tang, X.; Ren, Y.; Tang, C.; Du, J. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. *Arterioscler. Thromb. Vasc. Biol.* 2009, 29, 173–179. [CrossRef] [PubMed]
12. Desai, K.M.; Chang, T.; Untereiner, A.; Wu, L. Hydrogen sulfide and the metabolic syndrome. *Expert Rev. Clin. Pharmacol.* 2011, 4, 63–73. [CrossRef] [PubMed]
13. Panagaki, T.; Randi, E.B.; Augsburger, F.; Szabo, C. Overproduction of H$_2$S, generated by CBS, inhibits mitochondrial Complex IV and suppresses oxidative phosphorylation in Down syndrome. *Proc. Natl. Acad. Sci. USA* 2019, 116, 18769–18771. [CrossRef]
14. Paul, B.D.; Snyder, S.H. Gasotransmitter hydrogen sulfide signaling in neuronal health and disease. *Biochem. Pharmacol.* 2018, 149, 101–109. [CrossRef] [PubMed]
15. Wu, D.; Si, W.; Wang, M.; Lv, S.; Ji, A.; Li, Y. Hydrogen sulfide in cancer: Friend or foe? *Nitric Oxide* 2015, 50, 38–45. [CrossRef]
16. Meram, A.T.; Chen, J.; Patel, S.; Kim, D.D.; Shirley, B.; Covello, P.; Coppola, D.; Wei, E.X.; Ghali, G.; Kevil, C.G. Hydrogen Sulfide Is Increased in Oral Squamous Cell Carcinoma Compared to Adjacent Benign Oral Mucosa. *Anticancer Res.* 2018, 38, 3843–3852. [CrossRef] [PubMed]
17. Tabibzadeh, S. Nature creates, adapts, protects and sustains life using hydrogen sulfide. *Front. Biosci.* 2016, 21, 528–560. [CrossRef] [PubMed]
18. Kolluru, G.K.; Shen, X.; Bir, S.C.; Kevil, C.G. Hydrogen sulfide chemical biology: Pathophysiological roles and detection. *Nitric Oxide* 2013, 35, 5–20. [CrossRef] [PubMed]
19. Cuevasanta, E.; Denicola, A.; Alvarez, B.; Moller, M.N. Solubility and permeation of hydrogen sulfide in lipid membranes. *PLoS ONE* 2012, 7, e34562. [CrossRef] [PubMed]
20. Filipovic, M.R.; Zivanovic, J.; Alvarez, B.; Banerjee, R. Chemical Biology of H$_2$S Signaling through Persulfidation. *Chem. Rev.* 2018, 118, 1253–1337. [CrossRef]
21. Kimura, Y.; Kimura, H. Hydrogen sulfide protects neurons from oxidative stress. FASEB J. 2004, 18, 1165–1167. [CrossRef]

22. Whiteman, M.; Armstrong, J.S.; Chu, S.H.; Jia-Ling, S.; Wong, B.S.; Cheung, N.S.; Halliwell, B.; Moore, P.K. The novel neurmodulator hydrogen sulfide: An endogenous peroxynitrite ‘scavenger’. J. Neurochem. 2004, 90, 765–768. [CrossRef]

23. Whiteman, M.; Cheung, N.S.; Zhu, Y.-Z.; Chu, S.H.; Siau, J.L.; Wong, B.S.; Armstrong, J.S.; Moore, P.K. Hydrogen sulphide: A novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? Biochem. Biophys. Res. Commun. 2005, 326, 794–798. [CrossRef] [PubMed]

24. Whiteman, M.; Li, L.; Kostetski, I.; Chu, S.H.; Siau, J.L.; Wong, B.S.; Armstrong, J.S.; Moore, P.K. Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. Biochem. Biophys. Res. Commun. 2006, 343, 303–310. [CrossRef]

25. Olson, K.; DeLeon, E.R.; Liu, F. Controversies in hydrogen sulfide biology. Free Radic. Biol. Med. 2012, 52, 2276–2283. [CrossRef] [PubMed]

26. Honda, K.; Hishiki, T.; Yamamoto, S.; Yamamoto, T.; Miura, N.; Kubo, A.; Itoh, M.; Chen, W.Y.; Garcia-Berenguera, M.A.; Gutiérrez-Merino, C.; Wardman, P.; Denicola, A.; et al. Reactivity of hydrogen sulfide with peroxynitrite and other oxidants of biological interest. Free Radic. Biol. Med. 2011, 50, 196–205. [CrossRef] [PubMed]

27. Vitvitsky, V.; Kabil, O.; Banerjee, R. High turnover rates for hydrogen sulfide allow for rapid regulation of its tissue concentrations. Antioxid. Redox. Signal. 2012, 17, 22–31. [CrossRef]

28. Gutsch, M.; Pauleau, A.-L.; Marty, L.; Brach, T.; Wabnitz, G.H.; Samstag, Y.; Meyer, A.J.; Dick, T.P. Real-time imaging of the intracellular glutathione redox potential. Nat. Methods 2008, 5, 553–559. [CrossRef] [PubMed]

29. Shen, X.; Peter, E.A.; Bir, S.; Wang, R.; Kevil, C.G. Analytical measurement of discrete hydrogen sulfide pools in biological specimens. Free Radic. Biol. Med. 2012, 52, 2276–2283. [CrossRef] [PubMed]

30. Lowicka, E.; Beltowski, J. Hydrogen sulfide (H2S)—The third gas of interest for pharmacologists. Pharmacol. Rep. 2007, 59, 4–24. [CrossRef]

31. Rajendran, S.; Shen, X.; Gleave, J.; Kolluru, G.K.; Kevil, C.G. Nitric Oxide and Hydrogen Sulphide Regulation of Ischemic Vascular Growth and Remodeling. Compr. Physiol. 2019, 9, 1213–1247. [PubMed]

32. Shibuya, N.; Tanaka, M.; Yoshida, M.; Ogasawara, Y.; Toyogawa, T.; Ishii, K.; Kimura, H. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid. Redox. Signal. 2009, 11, 703–714. [CrossRef]

33. Kimura, Y.; Toyofuku, Y.; Koike, S.; Shibuya, N.; Nagahara, N.; Lefer, D.; Ogasawara, Y.; Kimura, H. Identification of H2S and H2S2 produced by 3-mercaptoppyruvate sulfurtransferase in the brain. Sci. Rep. 2015, 5, 14774. [CrossRef] [PubMed]

34. Fukushima, J.M.; Ignarro, L.J.; Nagy, P.; Wink, D.A.; Kevil, C.G.; Feelsch, M.; Cortese-Krott, M.M.; Bianco, C.L.; Kumagai, Y.; Hobbs, A.J.; et al. Biological hydrosulfides and related polysulfides—A new concept and perspective in redox biology. FEBS Lett. 2018, 592, 2140–2152. [CrossRef] [PubMed]

35. Iida, T.; Sawa, T.; Ibara, H.; Tsuuchiya, Y.; Watanabe, Y.; Kumagai, Y.; Suehara, M.; Motohashi, H.; Fujii, S.; Matsunaga, T.; et al. Reactive cysteine persulfides and S-polythiolation regulate oxidative stress and redox signaling. Proc. Natl. Acad. Sci. USA 2014, 111, 7606–7611. [PubMed]

36. Honda, K.; Hishiki, T.; Yamamoto, S.; Yamamoto, T.; Miura, N.; Kubo, A.; Itoh, M.; Chen, W.Y.; Takano, M.; Yoshikawa, T.; et al. On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits ovarian cancer to predict post-operative chemosensitivity. Redox Biol. 2021, 41, 101926. [CrossRef]

37. Akaite, T.; Ida, T.; Wei, Y.Y.; Nishida, M.; Kumagai, Y.; Alam, M.; Ibara, H.; Sawa, T.; Matsunaga, T.; Kasamatsu, S.; et al. Cysteinyl-tRNA synthetase governs cysteine polysulfidation and mitochondrial bioenergetics. Nat. Commun. 2017, 8, 1177. [CrossRef] [PubMed]

38. Yang, J.; Minkler, P.; Grove, D.; Wang, R.; Willard, B.; Dveik, R.; Hine, C. Non-enzymatic hydrogen sulfide production from cysteine in blood is catalyzed by iron and vitamin B6. Commun. Biol. 2019, 2, 194. [CrossRef] [PubMed]

39. Shen, X.; Carlström, M.; Borniquel, S.; Jädert, C.; Kevil, C.G.; Lundberg, J.O. Microbial regulation of host hydrogen sulfide bioavailability and metabolism. Free Radic. Biol. Med. 2013, 60, 195–200. [CrossRef]

40. Vasas, A.; Döka, E.; Fábián, I.; Nagy, P. Kinetic and thermodynamic studies on the disulfide-bond reducing potential of hydrogen sulfide. Nitric Oxide 2015, 46, 93–101. [CrossRef] [PubMed]

41. Dekker, E.; Tanis, P.J.; Fäuleg, J.L.A.; Kasi, P.M.; Wallace, M.B. Colorectal cancer. Lancet 2019, 394, 1467–1480. [CrossRef]

42. Szabo, C.; Coletta, C.; Chao, C.; Módis, K.; Szczesny, B.; Papapetropoulos, A.; Hellmich, M.R. Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 12474–12479. [CrossRef] [PubMed]

43. Módis, K.; Coletta, C.; Asimakopoulou, A.; Szczesny, B.; Chao, C.; Papapetropoulos, A.; Hellmich, M.R.; Szabo, C. Effect of S-adenosyl-L-methionine (SAM), an allosteric activator of cystathionine-beta-synthase (CBS) on colorectal cancer cell proliferation and bioenergetics in vitro. Nitric Oxide 2014, 41, 146–156. [CrossRef] [PubMed]

44. Phillips, C.M.; Zatarain, J.R.; Nicholls, M.E.; Porter, C.; Widen, S.G.; Thakii, K.; Johnson, P.; Jawad, M.U.; Moyer, M.P.; Randall, J.W.; et al. Upregulation of Cystathionine-β-Synthase in Colonic Epithelia Reprograms Metabolism and Promotes Carcinogenesis. Cancer Res. 2017, 77, 5741–5754. [CrossRef]

45. Wen, J.; Min, X.; Shen, M.; Hua, Q.; Han, Y.; Zhao, L.; Liu, L.; Huang, G.; Liu, J.; Zhao, X. ACLY facilitates colon cancer cell metastasis by CTNNB1. J. Exp. Clin. Cancer Res. 2019, 38, 401. [CrossRef] [PubMed]

46. Asencção, K.; Dilek, N.; Augsburger, F.; Panagaki, T.; Zuhra, K.; Szabo, C. Pharmacological induction of mesenchymal-epithelial transition via inhibition of H2S biosynthesis and consequent suppression of ACLY activity in colon cancer cells. Pharmacol. Res. 2021, 165, 105393. [CrossRef]
47. Chen, S.; Yue, T.; Huang, Z.; Zhu, J.; Bu, D.; Wang, X.; Pan, Y.; Liu, Y.; Wang, P. Inhibition of hydrogen sulfide synthesis reverses acquired resistance to 5-FU through miR-215-5p-EREG/TYMS axis in colon cancer cells. *Cancer Lett.* 2019, 466, 49–60. [CrossRef]

48. Yue, T.; Zuo, S.; Bu, D.; Zhu, J.; Chen, S.; Ma, Y.; Ma, J.; Guo, S.; Wen, L.; Zhang, X.; et al. Amino-oxyacetic acid (AOAA) sensitizes colon cancer cells to oxaliplatin via exaggerating apoptosis induced by ROS. *J. Cancer* 2020, 11, 1825–1838. [CrossRef]

49. Untereiner, A.A.; Pavlidou, A.; Druzhyna, N.; Papapetropoulos, A.; Hellmich, M.R.; Szabo, C. Drug resistance induces the upregulation of H2S-producing enzymes in HCT116 colon cancer cells. *Biochem. Pharmacol.* 2018, 149, 174–185. [CrossRef]

50. Jelovac, D.; Armstrong, D.K. Recent progress in the diagnosis and treatment of ovarian cancer. *CA Cancer J. Clin.* 2011, 61, 183–203. [CrossRef]

51. Bhattacharyya, S.; Saha, S.; Giri, K.; Lanza, I.R.; Jennings, N.B.; Lönnroth-Köhler, I.; Lopez-Berestein, G.; Basal, E.; Weaver, A.L.; et al. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. *PLoS ONE* 2013, 8, e79167. [CrossRef]

52. Chakraborty, P.K.; Murphy, B.; Mustafi, S.B.; Dey, A.; Xiong, Y.; Rao, G.; Naz, S.; Zhang, M.; Yang, D.; Dhanasekaran, D.N.; et al. Cystathionine beta-synthase regulates mitochondrial morphogenesis in ovarian cancer. *FASEB J.* 2018, 32, 4145–4157. [CrossRef]

53. Benson, J.R.; Jatoi, I. The global breast cancer burden. *Future Oncol.* 2012, 8, 697–702. [CrossRef] [PubMed]

54. Sen, S.; Kawahara, B.; Mahata, S.K.; Tsai, R.; Yoon, A.; Hu-Moore, K.; Villanueva, C.; Parameshwar, P.; et al. Cystathionine: A novel oncometabolite in human breast cancer. *Arch. Biochem. Biophys.* 2016, 469, 90–102. [CrossRef] [PubMed]

55. Sen, S.; Kawahara, B.; Gupta, D.; Tsai, R.; Khachatryan, M.; Roy-Chowdhuri, S.; Bose, S.; Hong, H.; Farias-Eisner, R.; et al. Role of cystathionine beta-synthase in human breast cancer. *Free Radic. Biol. Med.* 2015, 86, 228–238. [CrossRef] [PubMed]

56. You, J.; Shi, X.; Li, L.; Wang, L.; Han, H.; Fang, G.; Kang, W.; Wang, T. Cystathionine-gamma-lyase promotes tumor angiogenesis. *Oncotarget* 2017, 8, 65677–65686. [CrossRef]

57. da Silva, J.L.; Nunes, N.C.C.; Izetti, P.; de Mesquita, G.G.; de Mello, A.C. Triple negative breast cancer: A thorough review of biomarkers. *Crit. Rev. Oncol. Hematol.* 2020, 145, 102855. [CrossRef] [PubMed]

58. Wang, L.; Shi, H.; Liu, Y.; Zhang, W.; Duan, X.; Li, M.; Shi, X.; Wang, T. Cystathionine-gamma-lyase promotes the metastasis of breast cancer via the VEGF signaling pathway. *Int. J. Oncol.* 2019, 55, 473–487. [PubMed]

59. Liu, Y.; Wang, L.; Zhang, X.; Deng, Y.; Pan, L.; Li, H.; Shi, X.; Wang, T. A novel cystathionine gamma-lyase inhibitor, I194496, inhibits the growth and metastasis of human TNBC via downregulating multiple signaling pathways. *Scien. Rep.* 2021, 11, 8963. [CrossRef] [PubMed]

60. Chakraborty, P.K.; Murphy, B.; Mustafi, S.B.; Dey, A.; Xiong, Y.; Rao, G.; Naz, S.; Zhang, M.; Yang, D.; Dhanasekaran, D.N.; et al. Cystathionine beta-synthase regulates mitochondrial morphogenesis in ovarian cancer. *FASEB J.* 2018, 32, 4145–4157. [CrossRef]

61. Gai, J.-W.; Qin, W.; Liu, M.; Wang, H.-F.; Zhang, M.; Ma, G.-M.; Liu, G.-M.; Song, W.-H.; et al. Expression profile of hydrogen sulfide and its synthases correlates with tumor stage and grade in urothelial cell carcinoma of bladder. *Int. J. Clin. Exp. Pathol.* 2014, 7, 1818–1824. [PubMed]

62. Liu, H.; Chang, J.; Zhao, Z.; Li, Y.; Hou, J. Effects of exogenous hydrogen sulfide on the proliferation and invasion of human bladder cancer cells. *J. Cancer Res. Ther.* 2017, 13, 829–832. [CrossRef]

63. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN. *Int. J. Cancer* 2012, 136, E359–E386. [CrossRef]

64. Sonke, E.; Verrydt, M.; Postenka, C.O.; Pardhan, S.; Willie, C.J.; Mazzola, C.R.; Hammers, M.D.; Pluth, M.D.; Lobb, I.; Power, N.E.; et al. Inhibition of endogenous hydrogen sulfide production in clear-cell renal cell carcinoma cell lines and xenografts restricts tumor growth, survival and angiogenic potential. *Nitric Oxide* 2015, 49, 26–39. [CrossRef]

65. Shackelford, R.E.; Abdulsattar, J.; Wei, E.X.; Cotelingam, J.; Coppola, D.; Herrera, G.A. Increased Nicotinamide Phosphoribosyltransferase and Cystathionine-β-Synthase in Renal Oncocytomas, Renal Urothelial Carcinoma, and Renal Clear Cell Carcinoma. *Anticancer Res.* 2017, 37, 3423–3427.

66. Breza, J.; Soltsysova, A.; Hudecova, S.; Penesova, A.; Szadvari, I.; Babula, P.; Chovancova, B.; Lencsoeva, L.; Pos, O.; Breza, J. Endogenous H2S Producing Enzymes are involved in apoptosis induction in clear cell renal cell carcinoma. *BMC Cancer* 2018, 18, 541. [CrossRef] [PubMed]

67. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics. *CA Cancer J. Clin.* 2015, 65, 87–108. [CrossRef] [PubMed]

68. Wang, Y.H.; Huang, J.T.; Chen, W.L.; Wang, R.H.; Kao, M.C.; Pan, Y.R.; Chan, S.H.; Tsai, K.W.; Kung, H.J.; Lin, K.T. Dysregulation of cystathionine gamma-lyase promotes prostate cancer progression and metastasis. *EMBO Rep.* 2019, 20, e45986. [CrossRef] [PubMed]

69. Zhao, K.; Li, S.; Wu, L.; Lai, C.; Yang, G. Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module. *J. Biol. Chem.* 2014, 289, 20824–20835. [CrossRef]

70. Schlumberger, M.J. Papillary and follicular thyroid carcinoma. *N. Engl. J. Med.* 1998, 338, 297–306. [CrossRef]

71. Turbat-Herrera, E.A.; Kilpatrick, M.J.; Chen, J.; Meram, A.T.; Cotelingam, J.; Ghalie, G.; Kevill, C.G.; Coppola, D.; Shackelford, R.E. Cystathione-β-Synthase Is Increased in Thyroid Malignancies. *Anticancer Res.* 2018, 38, 6085–6090. [CrossRef] [PubMed]

72. Xu, Y.; Ma, N.; Wei, P.; Zeng, Z.; Meng, J. Expression of hydrogen sulfide synthases and Hh signaling pathway components correlate with the clinicopathological characteristics of papillary thyroid cancer patients. *Int. J. Clin. Exp. Pathol.* 2018, 11, 1818–1824. [PubMed]
73. Wu, D.; Li, J.; Zhang, Q.; Tian, W.; Zhong, P.; Liu, Z.; Wang, H.; Wang, H.; Ji, A.; Li, Y. Exogenous Hydrogen Sulfide Regulates the Growth of Human Thyroid Carcinoma Cells. *Oxid. Med. Cell. Longev.* 2019, 16, 6927298. [CrossRef] [PubMed]

74. Szczesny, B.; Marcatti, M.; Zatarain, J.R.; Druzhyna, N.; Wiktorowicz, J.E.; Nagy, P.; Hellmich, M.R.; Szabo, C. Inhibition of hydrogen sulfide biosynthesis sensitizes lung adenocarcinoma to chemotherapeutic drugs by inhibiting mitochondrial DNA Repair and suppressing cellular bioenergetics. *Sci. Rep.* 2016, 6, 36125. [CrossRef]

75. Ali, Z.; Yousaf, N.; Larkin, J. Melanoma epidemiology, biology and prognosis. *EJC Suppl.* 2013, 11, 81–91. [CrossRef]

76. Panza, E.; De Cicco, P.; Armogida, C.; Scognamiglio, G.; Gigantino, V.; Botti, G.; Germano, D.; Napolitano, M.; Papapetropoulos, A.; Bucci, M.; et al. Role of the cystathionine gamma lyase/hydrogen sulfide pathway in human melanoma progression. *Pigment Cell Melanoma Res.* 2015, 28, 61–72. [CrossRef]

77. Gu, X.; Zhu, Y.Z. Therapeutic applications of organosulfur compounds as novel hydrogen sulfide donors and/or mediators. *Expert. Rev. Clin. Pharmacol.* 2011, 4, 123–133. [CrossRef]

78. Szabo, C.; Papapetropoulos, A. International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. *Pharmacol. Rev.* 2017, 69, 497–564. [CrossRef]

79. Ueda, Y.; Richmond, A. NF-kB activation in melanoma. *Pigment Cell Res.* 2006, 19, 112–124. [CrossRef]

80. Warnakulasuriya, S. Global epidemiology of oral and oropharyngeal cancer. *Oral Oncol.* 2019, 45, 309–316. [CrossRef]

81. Warnakulasuriya, S. Global epidemiology of oral and oropharyngeal cancer. *Oral Oncol.* 2019, 45, 309–316. [CrossRef]

82. Mitchell, S.; Vargas, J.; Hoffmann, A. Signaling via the NFκB system. *Wiley Interdiscip. Rev. Syst. Biol. Med.* 2016, 8, 227–241. [CrossRef]

83. Mustafa, A.K.; Gadalla, M.M.; Sen, N.; Kim, S.; Mu, W.; Gazi, S.K.; Barrow, R.K.; Yang, G.; Wang, R.; Synder, S.H. Hydrogen sulfide signaling in the NCI60 panel of human cancer cell lines. *Biochem. Pharmacol.* 2011, 82, 1825–1831. [CrossRef] [PubMed]

84. Greiner, R.; Palinkás, Z.; Básell, K.; Becher, D.; Antelmann, H.; Nagy, P.; Dick, T.P. Polysulfides link H2S to protein thiol oxidation. *Antioxid. Redox. Signal.* 2013, 19, 1749–1765. [CrossRef] [PubMed]

85. Kumar, S.; Huang, J.; Cushnir, J.R.; Španˇ el, P.; Smith, D.; Hanna, G.B. Selected ion flow tube-MS analysis of headspace vapor from volatile organic compounds in plasma for the diagnosis of lung adenocarcinoma to chemotherapeutic drugs by inhibiting mitochondrial DNA Repair and suppressing cellular bioenergetics. *Sci. Rep.* 2016, 6, 36125. [CrossRef] [PubMed]

86. Zhang, K.; Zhang, J.; Xi, Z.; Li, L.-Y.; Gu, X.; Zhang, Q.-Z.; Yi, L. A new H2S-specific near-infrared fluorescence-enhanced probe that can visualize the H2S-induced S-sulfhydration of lactate dehydrogenase a (LDHA) stimulates cellular bioenergetics in HCT116 colon cancer cells. *Biochem. Pharmacol.* 2017, 136, 86–98. [CrossRef]

87. Abdel-Fatah, T.M.A.; Middleton, F.K.; Arora, A.; Agarwal, D.; Chen, T.; Moseley, P.M.; Perry, C.; Doherty, R.; Chan, S.; Green, A.R.; et al. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. *Mol. Oncol.* 2015, 9, 569–585. [CrossRef] [PubMed]

88. Feng, W.; Dean, D.C.; Hornicek, F.J.; Wang, J.; Jia, Y.; Duan, Z.; Shi, H. ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer. *Ther. Adv. Med. Oncol.* 2020, 12, 1758835920982853. [CrossRef] [PubMed]
100. Li, C.-C.; Yang, J.-C.; Lu, M.-C.; Lee, C.-L.; Peng, C.-Y.; Hsu, W.-Y.; Dai, Y.-H.; Chang, F.-R.; Zhang, D.-Y.; Wu, W.-J. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. *Oncotarget* 2016, 7, 1947–1959. [CrossRef] [PubMed]

101. Sundar, R.; Brown, J.; Russo, A.I.; Yap, T.A. Targeting ATR in cancer medicine. *Curr. Probl. Cancer* 2017, 41, 302–315. [CrossRef]

102. Dilek, N.; Papapetropoulos, A.; Toliver-Kinsky, T.; Csaba Szabo, C. Hydrogen sulfide: An endogenous regulator of the immune system. *Pharmacol. Res.* 2020, 161, 105119. [CrossRef]

103. Cicco, P.D.; Ercolano, G.; Rubino, V.; Terrazzano, G.; Ruggiero, G.; Cirino, G.; Ianaro, A. Modulation of the functions of myeloid-derived suppressor cells: A new strategy of hydrogen sulfide anti-cancer effects. *Br. J. Pharmacol.* 2020, 177, 884–897. [CrossRef] [PubMed]

104. Zuhra, K.; Augsburger, F.; Majtan, T.; Szabo, C. Cystathionine-β-Synthase: Molecular regulation and pharmacological inhibition. *Biomolecules* 2020, 10, 697. [CrossRef]

105. Asimakopoulou, A.; Panopoulos, P.; Chasapis, C.T.; Coletta, C.; Zhou, Z.; Cirino, G.; Giannis, A.; Szabo, C.; Spyroulias, G.A.; Papapetropoulos, A. Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine γ lyase (CSE). *Br. J. Pharmacol.* 2013, 169, 922–932. [CrossRef] [PubMed]

106. Nebbioso, A.; Tambaro, F.P.; Dell’Aversana, C.; Altucci, L. Cancer epigenetics: Moving forward. *PLoS Genet.* 2008, 14, e1007362. [CrossRef] [PubMed]

107. Cao, X.; Ding, L.; Xie, Z.Z.; Yang, Y.; Whiteman, M.; Moore, P.K.; Bian, J.-S. A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer? *Antioxid. Redox Signal.* 2019, 31, 1–38. [CrossRef] [PubMed]